Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST substudy of olaparib lead-in plus durvalumab for homologous recombination-deficient advanced cancers
ACTRN12617001000392Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in cancer and Nonhematologic neoplasms, sponsored by University of Sydney. Primary endpoint: Disease control. Started Nov 2017; status: completed.
02
Drugs
olaparibdurvalumab
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12617001000392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001000392.